15-GBM-10-IT (ICT-107-301) A Phase III study of ICT-107 plus maintenance temozolomide (TMZ) in newly diagnosed GBM

Grants and Contracts Details

StatusFinished
Effective start/end date12/3/155/2/18

Funding

  • ImmunoCellular Therapeutics Limited: $54,785.00